Business & Finance India's Panacea Biotec to produce 100mn Sputnik V doses annually: RDIF Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually. Published April 5, 2021 Updated April 5, 2021 06:04pm Save Saved 1 min comment Comments By Reuters Add BRecorder as a trusted source on Google MOSCOW: Indian biotech firm Panacea Biotec Ltd has agreed to produce 100 million doses of Russia's Sputnik V COVID-19 vaccine annually, the Russian Direct Investment Fund (RDIF), which markets the shot internationally, said on Monday. RDIF did not say when production would begin. Russia's Sputnik V vaccine Comments Comments are closed for this article. More Stories Key sectors: SIFC engages with Saudis on investments PSX extends gains, KSE-100 up over 400 points Six 'Fitna al Hindustan' terrorists killed in Panjgur IBO: ISPR Oil little changed on uncertainty over US-Iran peace deal Gold price drops by Rs1,469 per tola in Pakistan Rupee records gain against US dollar MPA Saqib Chadhar booked under PECA Act for allegedly harassing Momina Iqbal AJK elections scheduled for July 27; code of conduct enforced India's 'Cockroach Party' chief flies to New Delhi for protest Telecard recommends up to Rs564mn investment in Supernet rights issue Maritime minister urges urgent action on Arabian Sea heat crisis Browse all stories
Comments
Comments are closed for this article.